Novel Three-Drug Combinations of Bortezomib, Thalidomide, Dexamethasone and Lenalidomide for Newly Diagnosed Multiple Myeloma (MM)
Novel Three-Drug Combinations of Bortezomib, Thalidomide, Dexamethasone and Lenalidomide for Newly Diagnosed Multiple Myeloma (MM)
Slides from presentations at ASCO 2010 and transcribed comments from recent interviews with Robert Z Orlowski, MD, PhD (6/18/10) and Ravi Vij, MD (7/1/10)
Moreau P et al. Reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) is superior to bortezomib plus dexamethasone (VD) as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): Results of IFM2007-02 prospective randomized study. Proc ASCO 2010;Abstract 8014. Anderson KG et al. Lenalidomide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Updated results of a multicenter Phase I/II study. Proc ASCO 2010;Abstract 8016. |
||||||||